Advances in cognitive testing
(2025) p.161-184- Abstract
Recent developments in Alzheimer's disease biomarkers have significantly improved the early detection of Alzheimer's disease pathology (Hansson et al., 2023; Ossenkoppele and Hansson, 2021; Zetterberg and Blennow, 2021) [1-3]. However, while biomarkers for Alzheimer's disease can indicate the underlying brain pathology and have some predictive value for future cognitive decline, they do not provide information about cognitive Alzheimer's disease phenotypes, particularly in early disease stages (Dubois et al., 2021) [4], nor do they represent optimal measures of disease progression. Thus, it is of critical importance to identify, characterize, and monitor cognitive impairment in Alzheimer's disease using cognitive assessments. While... (More)
Recent developments in Alzheimer's disease biomarkers have significantly improved the early detection of Alzheimer's disease pathology (Hansson et al., 2023; Ossenkoppele and Hansson, 2021; Zetterberg and Blennow, 2021) [1-3]. However, while biomarkers for Alzheimer's disease can indicate the underlying brain pathology and have some predictive value for future cognitive decline, they do not provide information about cognitive Alzheimer's disease phenotypes, particularly in early disease stages (Dubois et al., 2021) [4], nor do they represent optimal measures of disease progression. Thus, it is of critical importance to identify, characterize, and monitor cognitive impairment in Alzheimer's disease using cognitive assessments. While capturing subtle cognitive changes and impairment in early disease stages still remains challenging (Weintraub et al., 2018) [5], several new approaches have recently been utilized to improve the early detection of subtle cognitive impairment and decline. In this chapter, I will first provide an overview of novel cognitive test paradigms that are tailored toward cognitive functions of which the functional anatomy overlaps with spatial patterns of accumulation of Alzheimer's disease pathology; these paradigms aim to capture signs of early impairment with greater sensitivity than previous measures. I will then illustrate new approaches to cognitive testing that build on recent technological developments (Koo and Vizer, 2019; Kourtis et al., 2019) [6,7] and aim to assess cognitive performance even outside clinical settings.
(Less)
- author
- Berron, David LU
- organization
- publishing date
- 2025
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- keywords
- AD pathology, Cognition, Digital biomarkers, Digital cognitive assessments, Functional brain systems, Remote and unsupervised cognitive assessments
- host publication
- Early Detection of Alzheimer's Disease : Biological and Technological Advances - Biological and Technological Advances
- pages
- 24 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:105005898947
- ISBN
- 9780128222409
- 9780128222416
- DOI
- 10.1016/B978-0-12-822240-9.00009-0
- language
- English
- LU publication?
- yes
- id
- f1cbe0d3-ddc6-4add-b6cd-df8c3dbc5b5f
- date added to LUP
- 2025-09-16 09:49:03
- date last changed
- 2025-09-30 11:29:55
@inbook{f1cbe0d3-ddc6-4add-b6cd-df8c3dbc5b5f,
abstract = {{<p>Recent developments in Alzheimer's disease biomarkers have significantly improved the early detection of Alzheimer's disease pathology (Hansson et al., 2023; Ossenkoppele and Hansson, 2021; Zetterberg and Blennow, 2021) [1-3]. However, while biomarkers for Alzheimer's disease can indicate the underlying brain pathology and have some predictive value for future cognitive decline, they do not provide information about cognitive Alzheimer's disease phenotypes, particularly in early disease stages (Dubois et al., 2021) [4], nor do they represent optimal measures of disease progression. Thus, it is of critical importance to identify, characterize, and monitor cognitive impairment in Alzheimer's disease using cognitive assessments. While capturing subtle cognitive changes and impairment in early disease stages still remains challenging (Weintraub et al., 2018) [5], several new approaches have recently been utilized to improve the early detection of subtle cognitive impairment and decline. In this chapter, I will first provide an overview of novel cognitive test paradigms that are tailored toward cognitive functions of which the functional anatomy overlaps with spatial patterns of accumulation of Alzheimer's disease pathology; these paradigms aim to capture signs of early impairment with greater sensitivity than previous measures. I will then illustrate new approaches to cognitive testing that build on recent technological developments (Koo and Vizer, 2019; Kourtis et al., 2019) [6,7] and aim to assess cognitive performance even outside clinical settings.</p>}},
author = {{Berron, David}},
booktitle = {{Early Detection of Alzheimer's Disease : Biological and Technological Advances}},
isbn = {{9780128222409}},
keywords = {{AD pathology; Cognition; Digital biomarkers; Digital cognitive assessments; Functional brain systems; Remote and unsupervised cognitive assessments}},
language = {{eng}},
pages = {{161--184}},
publisher = {{Elsevier}},
title = {{Advances in cognitive testing}},
url = {{http://dx.doi.org/10.1016/B978-0-12-822240-9.00009-0}},
doi = {{10.1016/B978-0-12-822240-9.00009-0}},
year = {{2025}},
}